BidaskClub lowered shares of Sarepta Therapeutics (NASDAQ:SRPT) from a buy rating to a hold rating in a research note published on Saturday morning.

Several other equities analysts have also weighed in on SRPT. William Blair reaffirmed an outperform rating on shares of Sarepta Therapeutics in a research report on Monday, February 5th. Zacks Investment Research raised shares of Sarepta Therapeutics from a sell rating to a hold rating in a research report on Wednesday, February 7th. Barclays reaffirmed a hold rating and set a $55.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, January 23rd. Janney Montgomery Scott assumed coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 3rd. They set a buy rating and a $75.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a buy rating on shares of Sarepta Therapeutics in a research report on Friday, October 27th. One analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have assigned a buy rating to the company. Sarepta Therapeutics has a consensus rating of Buy and a consensus price target of $64.65.

Sarepta Therapeutics (NASDAQ SRPT) opened at $58.87 on Friday. The firm has a market cap of $3,800.00, a P/E ratio of -28.86 and a beta of 1.49. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04. Sarepta Therapeutics has a 52-week low of $26.96 and a 52-week high of $68.90.

In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the transaction, the director now owns 13,333 shares of the company’s stock, valued at $745,181.37. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 9.60% of the company’s stock.

Several institutional investors have recently made changes to their positions in SRPT. Carillon Tower Advisers Inc. acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter worth $38,720,000. Jennison Associates LLC grew its stake in shares of Sarepta Therapeutics by 103.9% in the third quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock worth $51,885,000 after acquiring an additional 582,894 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of Sarepta Therapeutics in the third quarter worth $26,011,000. Gilder Gagnon Howe & Co. LLC grew its stake in shares of Sarepta Therapeutics by 3,599.4% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 534,087 shares of the biotechnology company’s stock worth $24,226,000 after acquiring an additional 519,650 shares during the last quarter. Finally, TimesSquare Capital Management LLC acquired a new stake in shares of Sarepta Therapeutics in the third quarter worth $21,521,000. Institutional investors and hedge funds own 82.41% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Sarepta Therapeutics (SRPT) Downgraded to Hold at BidaskClub” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2018/02/14/sarepta-therapeutics-srpt-downgraded-to-hold-at-bidaskclub.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.